The synergism between HDAC inhibitors and ErbB inhibitors was explored in a randomized phase II trial comparing first-generation EGFR inhibitor erlotinib with or without entinostat, an HDAC inhibitor, in 132 patients with advanced and treatment-naive NSCLC. Here, HDAC9 is linked to non-small cell lung carcinoma.